Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 23;10(2):79-86.
doi: 10.1055/s-0043-57247. eCollection 2023 Jun.

Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article

Affiliations
Review

Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article

Himanshu Singh. Glob Med Genet. .

Abstract

Breast cancer is a multifactor, multistage, and heterogeneous disease. Systemic treatment of breast cancer has changed significantly over the last decade. With a better knowledge of the pathogenesis, researchers and scientists have discovered numerous signaling pathways and synonymous therapeutic targets in breast cancer. Because of the molecular nature of breast cancer, which makes it difficult to understand, previous attempts to treat or prevent it have failed. However, recent decades have provided effective therapeutic targets for treatment. In this review, literature or information on various targeted therapy for breast cancer is discussed. English language articles were explored in numerous directory or databases like PubMed, Web of Sciences, Google Scholar, ScienceDirect, and Scopus. The important keywords used for searching databases are "Breast cancer," "Targeted therapy in breast cancer," "Therapeutic drugs in breast cancer," and "Molecular targets in breast cancer."

Keywords: breast cancer; molecular targets in breast cancer; precision medicine in breast cancer; targeted therapy in breast cancer; therapeutic drugs in breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

References

    1. Sledge G W, Jr, Miller K D. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer. 2003;39(12):1668–1675. - PubMed
    1. Ingvarsson S. Genetics of breast cancer. Drugs Today (Barc) 2004;40(12):991–1002. - PubMed
    1. Kenemans P, Verstraeten R A, Verheijen R HM. Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas. 2004;49(01):34–43. - PubMed
    1. Eniu A. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab. J BUON. 2007;12 01:S119–S126. - PubMed
    1. Modi S, D'Andrea G, Norton L. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer. 2006;7(03):270–277. - PubMed